Hemispherx Biopharma to Present on January 15 at the Biotech Showcase Held in Conjunction With the 32nd JP Morgan Healthcare ...
January 13 2014 - 8:00AM
Hemispherx Biopharma (NYSE MKT:HEB), today announced it will make a
presentation at the Biotech Showcase held in conjunction with the
32nd JP Morgan Healthcare Conference in San Francisco, California.
The JP Morgan Healthcare Conference is being held January 13-16,
2014. The Biotech Showcase is in its 6th year and expects over
1,700 attendees.
The company will provide a strategic overview of its business
during the live presentation and will be available to participate
in one-on-one meetings with investors who are registered to attend
the Biotech Showcase. The presentation will emphasize the company's
multiple clinical and bio-defense programs for its two platform
technologies, Alferon N® and Ampligen®, and will include new data
on potential treatment and/or prevention of emerging pandemic viral
threats.
Event: Biotech Showcase
Date: January 15, 2014
Time: 4:30 PM Pacific Standard Time
Location: Parc 55 Wyndam, San Francisco, California
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty
pharmaceutical company engaged in the manufacture and clinical
development of new drug entities for treatment of seriously
debilitating disorders. Hemispherx's flagship products include
Alferon N Injection® and the experimental therapeutics Ampligen®
and Alferon® LDO. Ampligen® is an experimental RNA nucleic
acid being developed for globally important debilitating diseases
and disorders of the immune system, including Chronic Fatigue
Syndrome. Hemispherx's platform technology includes components
for potential treatment of various severely debilitating and life
threatening diseases. Because both Ampligen® and Alferon® LDO
are experimental in nature, they are not designated safe and
effective by a regulatory authority for general use and are legally
available only through clinical trials. Hemispherx has patents
comprising its core intellectual property estate and a fully
commercialized product (Alferon N Injection®), approved for sale in
the U.S. and Argentina. The Company's Alferon N approval in
Argentina includes the use of Alferon N Injection (under the brand
name "Naturaferon") for use in any patients who fail or become
intolerant to recombinant interferon, including patients with
chronic active hepatitis C infection. The Company wholly owns
and exclusively operates a cGMP certified manufacturing facility in
the United States for commercial products. For more information
please visit www.hemispherx.net.
Forward-Looking Statements
To the extent that statements in this press release are not
strictly historical, all such statements are forward-looking, and
are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. Words such as
"potential," "potentially," "expects," "may" and similar
expressions are intended to identify forward-looking
statements. The inclusion of forward-looking statements should
not be regarded as a representation by Hemispherx that any of its
plans will be achieved. These forward-looking statements are
neither promises nor guarantees of future performance, and are
subject to a variety of risks and uncertainties, many of which are
beyond Hemispherx's control, which could cause actual results to
differ materially from those contemplated in these forward-looking
statements. Examples of such risks and uncertainties include
those set forth in the Disclosure Notice, above, as well as the
risks described in Hemispherx's filings with the Securities and
Exchange Commission, including the most recent reports on Forms
10-K, 10-Q and 8-K. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof, and Hemispherx undertakes no obligation to
update or revise the information contained in this press release,
whether as a result of new information, future events or
circumstances or otherwise revise or update this release to reflect
events or circumstances after the date hereof.
CONTACT: Company/Investor Contact:
Charles Jones
CJones & Associates Public Relations
888-557-6480
cjones@cjonespr.com